Tag: paxalisib
-
Kazia Therapeutics Reports Encouraging Early Signals from Paxalisib + Pembrolizumab in Late-Stage Metastatic TNBC
Overview of the Update Kazia Therapeutics (NASDAQ: KZIA) announced an interim clinical update from its ongoing Phase 1b study evaluating paxalisib in combination with pembrolizumab and chemotherapy for patients with late-stage (Stage IV) metastatic triple-negative breast cancer (TNBC). The release underscores encouraging preliminary clinical responses observed to date, reinforcing interest in paxalisib as part of…
-
Kazia Therapeutics Unveils Encouraging Early Responses for Paxalisib in Late-Stage TNBC
Overview of the Phase 1b Study Kazia Therapeutics has announced encouraging preliminary clinical responses from its ongoing Phase 1b trial evaluating paxalisib in combination with pembrolizumab and chemotherapy for patients with late-stage, Stage IV triple-negative breast cancer (TNBC). The study explores paxalisib, an AKT inhibitor, as part of a multi-agent regimen designed to address the…
-
Kazia Therapeutics Reports Encouraging Early Signals for Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer
Overview of the Phase 1b Study Kazia Therapeutics (NASDAQ: KZIA) announced encouraging early clinical responses from its ongoing Phase 1b trial evaluating paxalisib in combination with pembrolizumab and chemotherapy for patients with late-stage, metastatic triple-negative breast cancer (TNBC). The update signals potential activity for paxalisib, a PI3K/AKT/mTOR pathway inhibitor, when combined with standard immuno-oncology and…